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Abstract 
This work is aimed at describing the workflow for a methodology that combines chemoinformatics and 
pharmacoepidemiology methods and at reporting the first predictive model developed with this methodology. 
The new model is able to predict complex networks of AIDS prevalence in the US counties, taking into 
consideration the social determinants and activity/structure of anti-HIV drugs in preclinical assays. We 
trained different Artificial Neural Networks (ANNs) using as input information indices of social networks 
and molecular graphs. We used a Shannon information index based on the Gini coefficient to quantify the 
effect of income inequality in the social network. We obtained the data on AIDS prevalence and the Gini 
coefficient from the AIDSVu database of Emory University. We also used the Balaban information indices to 
quantify changes in the chemical structure of anti-HIV drugs. We obtained the data on anti-HIV drug activity 
and structure (SMILE codes) from the ChEMBL database. Last, we used Box-Jenkins moving average 
operators to quantify information about the deviations of drugs with respect to data subsets of reference 
(targets, organisms, experimental parameters, protocols). The best model found was a Linear Neural Network 
(LNN) with values of Accuracy, Specificity, and Sensitivity above 0.76 and AUROC > 0.80 in training and 
external validation series. This model generates a complex network of AIDS prevalence in the US at county 
level with respect to the preclinical activity of anti-HIV drugs in preclinical assays. To train/validate the 
model and predict the complex network we needed to analyze 43,249 data points including values of AIDS 
prevalence in 2,310 counties in the US vs ChEMBL results for 21,582 unique drugs, 9 viral or human protein 
targets, 4,856 protocols, and 10 possible experimental measures. 
 
 
 
 
1 Introduction 
The acquired immunodeficiency syndrome (AIDS)(1) caused by the human immunodeficiency 
virus (HIV) is still considered as one of the most life-threatening diseases, and the HIV(2, 3) 
pandemic continues to spread. Since the beginning of the epidemic, more than 60 million people 
have been infected with HIV, and over 25 million have died from the disease. Since the first case 
of AIDS was reported by the US in 1981, tremendous progress has been made in the prevention 
and treatment of HIV/AIDS,(4) especially in the development of antiretroviral therapy(5) that has 
proven to be life-saving to millions of people. Therefore, the discovery and development of novel, 
highly potent anti-HIV drugs remain imperative, although the eradication is still a difficult goal to 
achieve due to a low level of viral persistence in treated subjects.(6) 
 
In this context, different Computer-Aided Drug Design (CADD) techniques, useful to predict 
the behavior of anti-HIV drugs, may play an important role in reducing the number of preclinical 
and clinical studies. For instance, we could use chemoinformatics models that link the chemical 
structure of drugs with their biological activity. In fact, there are many reports of 
chemoinformatics models, useful to predict anti-HIV activity in preclinical assays.(7) In principle, 
we could upgrade these models to predict the anti-HIV activity of drugs not only in preclinical 
screening but also in clinical and pharmacoepidemiology studies. Such a model may become a 
very useful tool not only for the Pharmaceutical Industry in order to reduce clinical assays. They 
should ideally be useful also for Public entities responsible for implementation of Health policies 
in the phase IV of drug development. However, there are no reports of models useful to predict the 
performance of anti-HIV drugs in both preclinical and pharmacoepidemiology studies on large 
populations without carrying out clinical studies. We neither had at our disposal models able to 
extrapolate, at least, the performance of anti-HIV drugs from preclinical studies to epidemiology 
studies on large populations without carrying out clinical studies. 
 
A useful chemoinformatics-pharmacoepidemiology model should be multilevel by definition 
as it is expected to account for both molecular and population structure. It means that, in order to 
develop such computational models, we need to process different types of input data coming from 
many different levels of organization of matter. On the one hand, we need to introduce information 
about the anti-HIV drugs including at least the chemical structure of the drug (level i) and the 
preclinical assay information, such as biological targets (level ii), organisms (level iii), or assay 
protocols (level iv). On the other hand, we need to incorporate population structure descriptors 
(level v) that quantify the epidemiological and social and economic factors affecting the 
population selected for the study. Last, as populations in modern society are not close systems we 
should also quantify the effect of interaction of the population under study with other populations 
that may influence the pharmacoepidemiology study (level vi). The data for levels i--iv were 
obtained from public databases of biological activity of organic compounds. These databases 
accumulated immense data sets of experimental results of pharmacological trials for many 
compounds. For instance, ChEMBL (https://www.ebi.ac.uk/chembl/)(8, 9) is one of the biggest 
with more than 11,420,000 activity data for >1,295,500 compounds and 9,844 targets. 
Specifically, ChEMBL contains >43,000 outcomes for assays of anti-HIV compounds. 
 
In addition, we obtained the data for levels v and vi from public epidemiological databases. For 
instance, AIDSVu(10) (http://aidsvu.org/about-aidsvu/) is the most detailed publicly available 
view of HIV prevalence in the US. AIDSVu is a compilation of interactive online maps that 
displays the HIV prevalence data at the national, state, and local levels and by different 
demographics, including age, race, and sex. Researchers at the Rollins School of Public Health at 
Emory University compiled the county-level data displayed on AIDSVu from the CDC (U.S. 
Centers for Disease Control and Prevention). State, county, and city health departments, depending 
on the entity responsible for HIV surveillance provided data on the HIV prevalence at the ZIP 
code and census tract. An Advisory Committee and a Technical Advisory Group guide the project 
with representatives from federal agencies, state health departments, and nongovernmental 
organizations working in HIV prevention, care, and research. 
  
The formulation of mathematical models of this large data set from ChEMBL is very complex 
per se(9, 11) but becomes an even more complicated problem when AIDSVu data are added. This 
is not only a problem of analysis of a huge number of data points (Big Data),(12-17) it is also a 
problem of dealing with the mathematical representation/codification of such diverse information 
from many different levels of organization of matter and areas of scientific knowledge. We can 
talk about three features of the problem resulting from the combination of chemical, 
pharmacological, and epidemiological information: (1) multitargeting, (2) multiobjective, and/or 
(3) multiscaling features. The multitargeting nature of the problem(18-20) refers to the existence 
of multitarget compounds that can interact with more than one molecular or cellular target. The 
multiobjective optimization problem (MOOP)(21-25) refers to the necessity of 
prediction/optimization of results for different experimental measures obtained in different 
pharmacological assays. Last, multiscaling refers to the different structural levels of the 
organization (i–vi) of matter that input variables. It means that we need to develop models able to 
link the changes in the AIDS prevalence in a given a
th
 population with the changes in the 
biological activity of the q
th
 drug (dq), due to variations in the chemical structure, detected in 
preclinical assays carried out under a set of j
th
 conditions (cj). 
 
We can use numerical descriptors of the molecular graph of the drug. In particular, some of 
these parameters are useful to quantify information about the properties of molecular, biological, 
and/or social systems (information measures). For instance, Shannon’s entropy measures are 
universal parameters used to codify biologically relevant information in many systems. In the 
1970s Bonchev and Trinajstic et al. published some works about the use of Shannon’s entropy to 
calculate a structural information parameter.(26-29) Kier published other seminar works on the use 
of Shannon’s entropy to encode molecular structure in chemoinformatics studies in 1980.(29) In 
this context, a drug molecule is considered an information source. Many other authors used 
Shannon’s entropy parameters to encode small molecule structure.(30-35) Graham et al.(36-40) 
used entropy measures to study in depth the information properties of organic molecules. These 
concepts were extended to describe protein,(41, 42) DNA sequences,(43) or protein–protein 
interaction networks.(44) Mikoláš et al.(45) reviewed several studies about the use of entropy 
measures in functional magnetic resonance. In a recent work we have used Shannon entropy 
measures and the idea of Moving Average (MA) operators in a time series analysis with a similar 
purpose.(46) Additionally, information indices are graph-theoretical invariants that view the 
molecular graph as a source of different probability distributions to which information theory 
definitions can be applied. They can be considered a quantitative measure of the lack of structural 
homogeneity or the diversity of a graph, in this way being related to the symmetry associated with 
structure.(47-49) Ivanciuc and Balaban(50) defined the indices for simple and weighted molecular 
graphs and tested the information theory-indices for modeling alkane densities. Moreover, 
Ivanciuc et al.(51) also found that the information indices were extended for any symmetric 
molecular matrix derived from vertex-and edge-weighted molecular graphs. Dehmer et al.(52-55) 
mentioned the Balaban information indices(56) in their work about novel topological descriptors 
for biological networks. 
 
However, the codification of the molecular structure of the drug is only the first step here. We 
have information about a high number of assays carried out in very different conditions (cj) for the 
same or different targets, which may be molecular or not. The nonstructural information herein 
refers to different assay conditions (cj) like time, concentrations, temperature, cellular targets, 
tissues, organisms, etc. A possible solution may rely upon the use of the idea of MA operators 
used in a time series analysis with a similar purpose.(46) MA models became popular after the 
initial works conducted by Box and Jenkins.(57) In a time series analysis, MA models may 
combine other operators I = Integrated, AR = Autoregressive, N = Nonlinear operators, or X = 
Exogenous effects. In this sense, we can develop models like ARMA, ARIMA, VARIMA, 
ARIMAX, NARMA, etc., combining different operators. The MA operators used in time series are 
the average value of a characteristic of the system for different intervals of time or seasons. In 
multiobjective modeling, we calculate the MA operators as the average of the property of the 
system (molecular descriptors or others) for all drugs or targets with a specific response in an 
assay carried out at under a subset of conditions (cj). Consequently, our MA operator does not act 
over a time domain but over a subset of conditions of the pharmacological assays. The idea of 
application of MA operators to other domains different from time is gaining adepts due to its 
advantages. For instance, Botella-Rocamora et al.(58) developed a model map of diseases called 
SMARS: Spatial Moving Average Risk Smoothing. They applied the MA of time series theory to 
the spatial domain, making use of a spatial MA to define dependence on the risk of a disease 
occurring. 
 
Certainly, we can see this entire problem as the prediction of a complex network represented 
by the Boolean matrix L with elements Laq. That is, we have to seek a model able to assess the 
formation (Laq = 1) or not (Laq = 0) of links between nodes in a complex network of AIDS 
pharmacoepidemiology in the US. Two different classes of nodes make up this network, the first 
representing the US counties (a) and the other class of nodes representing drugs (dq). In the present 
context, we can use MA of properties of network nodes (drugs, proteins, organisms, counties, etc.) 
that form links (Laq) in a specific subset of conditions (cj). For this reason, we decided to call this 
strategy ALMA (Assessing of Links with Moving Averages) models. Speck-Planche and 
Cordeiro(59-61) have reported different multitarget models using the same type of ALMA 
approach. 
 
Last, we can use these information descriptors and MA operators as inputs for a Machine 
Learning (ML) algorithm. This ML has to seek the coefficients of the ALMA model able predict 
the correct links in L. The neural network approximates the operation of the human brain,(62, 63) 
and this initially ″trained″ or fed large amounts of data and rules about data relationships. ANNs 
are in general nonlinear algorithms with a high number of processors (called neurons) which, in a 
classic picture, are distributed in layers and act in parallel (neurons in the same layer) or in series 
(pairs of neurons connected in different layers). In recent years, ANNs(64, 65) have turned out to 
be a powerful method for various practical applications in a great variety of disciplines, and they 
can be used to find complex relationships between inputs and outputs or to find models in data. 
Another aspect of ANNs(66, 67) is that there are different architectures, which require different 
types of algorithms for training; the trained ANN do not need to be reprogrammed. 
2 Materials and Methods 
Linear and Nonlinear ALMA Models 
The ALMA models are useful to assess the formation of links in different complex networks 
that are representations of complex systems. They are adaptable to all types of molecular 
descriptors and/or graphs invariants or descriptors for complex networks. In this work, we tried to 
seek a classification model. The overall output of this model is Laq(cj)pred. This variable is a 
prediction of the observed variable Laq(cj)obs. Both the observed and predicted variables are 
discrete Boolean variables (1, 0). The observed variable takes the value Laq(cj)obs = 1 if the 
observed score Saq(cj)obs > input cutoff or Laq(cj)obs = 0 otherwise. In analogy, the predicted variable 
Laq(cj)pred = 1 if the predicted score Saq(cj)pred > output cutoff or Laq(cj)pred = 0 otherwise. 
 
More specifically, we can say that the value is Laq(cj)obs = 1 when the Saq(cj)obs = Drug-Disease 
Ratio = DDRaq(cj) > cutoff and Laq(cj)obs = 0 otherwise. We defined the ratio as follows: Saq(cj)obs = 
DDRaq(cj) = [Dq(cj)/Da]. We calculated the numerator term as Dq(cj) = δj·zq(cj) = δj·[vq(cj) – 
AVG(v(cj))]/SD(v(cj)). In this operator, vq(cj) is the value of biological activity (EC50, IC50, Ki, ..., 
etc.) reported in the ChEMBL database for the q
th
 drug assayed under the set of conditions cj = (cl, 
c2, c3, c4). The parameter δj is similar to a Kronecker delta function. The parameter δj = 1 when the 
biological activity parameter vq(cj) is directly proportional to the biological effect (e.g., K i values, 
Activity (%) values, etc.). Conversely, δj = −1 when the biological activity parameter vq(cj) is in 
inverse proportion to the biological effect (e.g., EC50 values, IC50 values, etc.). The parameter zq(cj) 
is the z-score of the biological activity that depends on the functions AVG and SD. These 
functions are the average and standard deviation of vq(cj) for all drugs assayed under the same 
conditions. In this sense, c1 = is the experimental measure of activity, c2 = is the protein target, c3 = 
is the organism that expresses the target, and c4 = is the assay protocol per se. In the denominator, 
we used the term Da that is the AIDS prevalence rate for the a
th
 county. We can conclude that 
Laq(cj)obs and consequently Laq(cj)pred depend on both the prevalence of the disease and the 
effectiveness of the drug due to the definition of DDRaq(cj). In Table 1, a simple example of 
calculation of MA operators is shown. In this example, we only use the condition (c2), i.e., 
Balaban information index U= I
q
1 and the target of the drug, to illustrate the method. First, we 
have the SMILE codes of the compounds obtained from ChEMBL. Next, using the DRAGON 
Software(68) we calculated the Balaban Information Indices (in this case only U = I
q
1). Afterward, 
we calculated ⟨Iq1⟩ the average of the information index I
q
1 for the compounds with the same 
targets. Last, we calculated the MA operators with the formula ΔIq1(c2) = (I
q
1 – ⟨I
q
1⟩c2. In our work, 
this method was applied to the 43,249 molecules characterized by different Balaban Information 
indices (U = I
q
1, V = I
q
2, X = I
q
3, Y = I
q
4) and assay conditions cj = (cl, c2, c3, c4). In addition, 
⟨Dq(cj)⟩ is the average value of the biological activity for all the drugs assayed under the same 
conditions. Consequently, ΔDq(cj) is an MA operator that accounts for the deviation of the 
biological activity of the drug Dq(cj) in a preclinical assay with respect to the average value 
⟨Dq(cj)⟩ of this activity for all drugs assayed under the same conditions cj. 
 
 
In order to seek a model able to predict Laq(cj)pred, we used as input different information 
descriptors for drugs and populations. In general, we refer to an information index I
q
k of type k
th
 
for the system (drug or county in this case) represented by a matrix L. The aim of this model is to 
predict scores Saq(cj) of the formation of links Laq using as input the structural information 
quantified by the indices I
a
0(t) for the population (county) and I
q
k of a given compound dq. The 
simplest model may be based on the additive hypothesis H0. The hypothesis H0 states that Saq(cj) = 
q
Sk + 
qj
Sk + 
as
Sk + e0. It means that it can be calculated as a summation of different scores or 
measures of factors plus a model error e0. We have three types of scores or factors divided into two 
subtypes. The first subtype includes the scores for drugs and the second subtype the scores for 
counties. The first scores 
q
Sk ≈ ek·p(cl)·I
q
k account for information on both the contributions of the 
k
th
 molecular descriptor and for the quality of raw data p(cl) to the final activity score Saq(cj). In 
fact, we used the probability p(c1) = 1.0; 0.75; or 0.5 for data curated in CHEMBL database at 
expert, intermediate, or autocuration levels, respectively. The second scores 
qj
Sk ≈ ekj·ΔI
q
k(cj) 
account for the contributions of deviations ΔIqk(cj) = (I
q
k – ⟨I
q
k⟩j) in the structure of the drug from 
the average of all those molecules assayed under the conditions cj. In order to test this hypothesis 
we used the information indices and their MA operators ΔIqk(cj) = I
q
k – ⟨I
q
k(cj)⟩ to express the 
different assay conditions for the drugs. We also used a simple information index I
a
0(t) for income 
inequality in the different counties. The linear model ALMA has the following general form: 
 
 
 
The reader should note that the predicted, output, or dependent variable Saq(cj) is not a discrete 
variable but a real-valued numerical score. However, the variable Saq(cj) is directly proportional to 
the observed variable (Laq). Please, note that all the parameters Saq(cj) => Laq(cj) => DDRaq(cj) => 
Dq(cj) form a series that in the last instance depends on (=>) the conditions of the initial preclinical 
assay used to measure the activity of the drug cj = (cl, c2, c3, c4). In general, cj refers to different 
boundary conditions for the assay, e.g., targets, assays, cellular lines, organisms, organs, etc. In 
this sense, c1 = is the experimental measure of activity, c2 = is the protein target, c3 = is the 
organism that expresses the target, and c4 = is the assay protocol per se. Some inputs of the models 
depend on parameters of the type of deviations ΔIqk(cj), which are similar to the MA operators 
used in the time series analysis for ARIMA models and others.(57) This means that, first, we add 
up for instance the values of I
q
k for all the nj drugs under the assay conditions cj. Next, we divide 
this sum by the number of compounds nj under this condition. 
 
 
 
 
 
In order to seek the coefficients of the model, we can use a linear classification technique like 
ANN implemented in the STASTITICA 6.0 software package.(69) The statistical parameters used 
to corroborate the model were as follows: Number of cases in training (N), and overall values of 
Specificity (Sp), Sensitivity (Sn), and Accuracy (Ac).(70) 
CHEMBL Data Set of Drugs 
We downloaded from the public database CHEMBL a general data set composed of >8,000 
multiplexing assay end points (results of multiple assays).(8, 9) The data set used to perform the 
model included N = 43,249 statistical cases made up of Nd = 21,582 unique drugs. These drugs 
have been assayed one by one in at least one out of 10 possible standard type measures determined 
in at least one out of 4,856 different assays (experimental protocols reported as different in 
ChEMBL). Each assay involved, in turn, at least one out of 9 nonmolecular or protein targets 
expressed in tissues, cells, or viral particles of at least one out of 5 different organisms (including 
human cells lines). 
Balaban Information Indices of Molecular Graphs of Drugs 
The Balaban information indices(56) U, V, X, and Y are very useful to quantify information 
about the chemical structure of drugs.(71) These indices use some the following parameters: σx = 
vertex distance degree of x
th
 atom (i.e., sum of topological distances from the considered atom to 
any other atom), dxy is the topological distance between atoms x
th
 and y
th
 atoms; n is the number of 
non-H atoms. Other parameters used are 
g
fx = the number of distances from the x
th
 vertex equal to 
g and ηx = the eccentricity of the x
th
 atom (i.e., the maximum topological distance from the 
considered atom). We denoted these indices in the present work as I
q
k. In this notation, the letter I 
stands for the information index, q indicates the number of order (label) of the drug in the data set, 
and k indicates the type of index. The mathematical formulas for calculation of these indices are 
 
 
 
 
 
AIDSvu Data Set of AIDS Prevalence in the US at County Level 
Data were drawn from the AIDSVu database of the Rollins School of Public Health at Emory 
University (www.aidsvu.org). We downloaded the values of epidemiological variables for AIDS 
in the US at county level from the public database. The values used in this study included the 
percentage of adults/adolescents living with an HIV diagnosis in 2010 per 100,000 populations. 
The county-level HIV surveillance data displayed on AIDSVu are estimated data for persons aged 
13 and older living with an HIV infection diagnosis. All race groups are non-Hispanic, and the 
Hispanic/Latino ethnicity is inclusive of all races. Sex is defined as “sex at birth”. Data are not 
displayed at the county level for Asians, Native Hawaiians/Other Pacific Islanders, and American 
Indians/Alaska Natives because these data do not meet CDC’s criteria for statistical reliability, 
data quality, or confidentiality due to small population denominators and HIV case counts. The 
total number of counties is na = 2,310. 
Shannon Information Indices of Income Inequality 
We can calculate an information index to quantify the possibility of AIDS 
spreading/prevalence in different counties (a) of the US. Let be an initial situation in which each 
county has a value of AIDS prevalence rate Da at the initial time (t0 = 2010). We used here a 
simple information index I
a
0(t) for income inequality in the different counties that year. This index 
depends on the probability 
0
pa with which the county presents certain income inequality. We set 
here this probability 
0
pa = Ga. In this definition, Ga is the Gini measure of income inequality in the 
a
th
 county of (a) given state(s) in the US.(72) The class of information indices selected by us was 
the Shannon entropy indices.(73) 
 
 
 
  
3 Results and Discussion 
Definition of the Algorithm 
In this work, we report for the first time a model based on information indices of chemical 
structure, biological assay, and county level income inequality. The model is able to link the 
deviations in the AIDS prevalence in the a
th
 county with the changes in the biological activity of 
the q
th
 drug (dq). In so doing, the model considers the biological activity of anti-HIV compounds 
detected in preclinical assays carried out under a set of j
th
 conditions (cj). Using this type of model, 
we can predict the pharmacoepidemiology complex network for AIDS in the United States at 
county level. 
 
First, we propose a new algorithm to construct this type of models. The algorithm/model used 
as input both drug structures and preclinical information as well as county income inequality data. 
We understand here as algorithm the series of all steps given in different stages in order to seek 
and use the model. We illustrate the different steps of this algorithm in Figure 1. The stages of the 
algorithm proposed are the following: (i) data compilation, (ii) data preprocessing, (iii) calculation 
of inputs, (iv) development, and use of the model. These stages are similar and divided into two 
parallel branches (A and B). Both branches have different steps, one for the chemical and 
biological information of drugs and the other for the information about county 
pharmacoepidemiology. Next, after the preprocessing stage (ii), the two branches are joined into a 
single branch (C) that enters a cycle of training vs validation of the different ANN models and 
ends with the selection and use of the best model found. In this context, we understand as model 
the ANN trained and validated in the final step of the algorithm. The most important steps for the 
branches A and B are the following (the software/databased used are between round brackets): 
 
a.1. Gathering of the chemical structure and biological activity information from public sources 
(ChEMBL). 
a.2. Processing of the information about molecular structure (SMILE codes) and biological 
activity (EXCEL). 
a.3. Calculation of I
q
k values and MA operators for the molecules (DRAGON,(68) EXCEL). 
b.1. Downloading the US AIDS prevalence and income inequality data (AIDSVu). 
b.2. Calculation of the simple information index I
a
0(t) for income inequality in the different 
counties. 
c.5. Training and validation of ANN predictive models (STATISTICA).(69) 
 
 
 
Figure 1. Flowchart of all steps given to construct the ANNs for the Drug-
County Pharmacoepidemiology model in the United States. 
Model Training and Validation 
In the first step, we calculated the values drug-disease ratio DDRaq(cj)obs for the 43,249 drug-
county pairs. After that, we carried out a cutoff scanning and found that we can split the data set 
into 11,089 cases with Laq(cj)obs = 1 and 32,160 cases with Laq(cj)obs = 0 using a cutoff = 500. This 
is 25.6% of the positive cases that ensure a ratio of above 1/4 of positive vs control cases. The data 
set used to train the model includes N = 32,437 statistical cases. The data set used to validate the 
model includes N = 10,812 statistical cases. The cases used in the validation set (external 
validation set) were never used to train the model. Overall, training + validation sets include N = 
43,249 statistical cases. Next, we calculated the values of the Balaban information indices I
q
k for 
all the drugs/organic compounds present in our ChEMBL subset (step a.2). Table 2 shows some 
examples of these values I
q
k for known drugs. In addition, in Table SM1 of the Supporting 
Information content we list the values of I
q
k for all the drugs studied. We can see that the 
information indices I
q
k have different numerical values for different molecular structures of drugs. 
After that, we calculated the average values of these indices ⟨Iqk⟩ for the different boundary 
conditions (cj). In Table 3, you can see some examples of these average values for different 
boundary conditions like targets, organisms, etc. After a visual inspection, one can note that the 
⟨Iq1⟩ values seem to distinguish more clearly between the different boundary conditions. For 
instance, they have differences in the range of 10–100 units for 9 different protein targets (4 HIV 
vs five human proteins) present in the data set. However, the other averages <I
q
k> with k > 1 seem 
to be worse at differentiating the proteins. In Table SM2 of the Supporting Information, we list the 
values of <I
q
k> for all the organisms, assay protocols, protein targets, and experimental measures 
studied. 
 
Next, we calculated the values of the information indices I
a
0(t) for different US counties. 
Consequently, we used only the I
a
0(t) as inputs for the model. After that, we obtained the ANN 
models using as input 19 descriptors: 4 Balaban information indices of the molecules (I
q
k), 14 MA 
operators (ΔIqk(cj)) for the different assay conditions for drugs (c1,c2,c3,c4), and the I
a
0(t) of the US 
counties. In Table 4, we illustrate the values of I
a
0(t) for some counties of different states. In Table 
SM3 of the Supporting Information, we list the values of I
a
0(t) for the 2,310 US counties studied 
here. 
 
Figure 2 shows the AUROC values for the different ANN models. The LNN network shows 
values of AUROC = 0.82 in the training and external validation set. These values are typical of a 
classifier with a classification behavior different from a random classifier (AUROC = 0.5).(70) 
The sensitivity analysis allowed us to quantify (rank) and order (ratio) into a sequence the 
importance of the different chemoinformatics vs pharmacoepidemiology inputs. This kind of 
model may be useful to predict different situations of interest in pharmacoepidemiology. For 
instance, the model is able to identify when the same drugs present a strong effect on population 
epidemiology for different counties (Laq(cj)pred = 1). Table 6 shows the predictions for some cases 
with the LNN model. In the table we can see that the model predicts Laq(cj)pred =1 for 
Nevirapine(75) in different counties, which is a drug Laq(cj)obs = 1 for these counties. In Table SM4 
of the Supporting Information, we provide the results predicted with the LNN model for all the 
cases in training and external validation series. 
  
Table 2. Values of Balaban Information Indices for Some Anti-HIV Compounds 
CMPD_ID name Iq1 I
q
2 I
q
3 I
q
4 
      
8 Ciprofloxacin 33.562 0.236 0.352 0.705 
28 Apigenin 29.885 0.27 0.407 0.789 
50 Quercetin 34.277 0.276 0.413 0.819 
54 Haloperidol 44.833 0.185 0.303 0.477 
57 Nevirapine 25.731 0.284 0.406 0.916 
169 Ursolic Acid 47.503 0.217 0.323 0.663 
58 Mitoxantrone 60.8 0.236 0.363 0.671 
61 Podofilox 41.071 0.211 0.314 0.644 
66 (+)-Taxifolin 34.277 0.276 0.413 0.819 
76 Chloroquine 42.46 0.26 0.414 0.696 
107 Colchicine 51.672 0.287 0.423 0.882 
114 Saquinavir 86.9 0.151 0.237 0.415 
115 Indinavir 76.144 0.147 0.233 0.403 
116 Amprenavir 69.801 0.221 0.342 0.621 
117 Chrysin 27.677 0.282 0.42 0.837 
129 Zidovudine 33.488 0.331 0.497 0.973 
141 Lamivudine 23.582 0.349 0.519 1.03 
150 Kaempferol 32.004 0.278 0.416 0.828 
151 Luteolin 32.088 0.267 0.404 0.78 
160 Cyclosporine 582.739 0.44 0.689 1.214 
163 Ritonavir 103.789 0.161 0.256 0.435 
164 Myricetin 36.608 0.275 0.412 0.817 
168 Oleanolic Acid 47.52 0.215 0.32 0.653 
193 Nifedipine 50.628 0.377 0.547 1.204 
413 Sirolimus 159.248 0.178 0.28 0.488 
483 Tenofovir 33.803 0.293 0.455 0.81 
484 Adefovir 31.274 0.282 0.443 0.764 
593 Delavirdine 52.159 0.166 0.267 0.439 
625 Thiabendazole 18.185 0.311 0.458 0.935 
713 Entecavir 29.767 0.29 0.43 0.875 
729 Lopinavir 90.532 0.173 0.271 0.477 
853 Zalcitabine 23.582 0.349 0.519 1.03 
885 Emtricitabine 25.889 0.35 0.52 1.041 
964 Disulfiram 60.801 0.685 1.063 1.887 
991 Stavudine 25.889 0.35 0.52 1.041 
7187 Costatolide 39.569 0.262 0.381 0.826 
1460 Didanosine 23.687 0.29 0.432 0.863 
6246 Ellagic Acid 29.481 0.287 0.412 0.927 
7187 Costatolide 39.569 0.262 0.381 0.826 
8260 Baicalein 29.825 0.28 0.418 0.83 
9352 Naringenin 29.885 0.27 0.407 0.789 
12014 Harman 18.019 0.355 0.502 1.146 
13134 Palinavir 95.629 0.142 0.226 0.386 
16901 Honokiol 36.232 0.315 0.478 0.909 
      
 
  
Table 3. Average Values of the Information Descriptors of Molecular Structure under Different Boundary Conditions 
c1 experimental measure N(cj) ⟨I
q
1⟩ ⟨I
q
2⟩ ⟨I
q
3⟩ ⟨I
q
4⟩ 
       
IC50 (nM) inhibitory concentration 50% 20332 64.303 0.209 0.324 0.587 
EC50 (nM) effective concentration 50% 14981 60.888 0.219 0.337 0.625 
Ki (nM) inhibitory constant 3736 78.878 0.180 0.282 0.501 
IC95 (nM) inhibitory concentration 95% 1290 59.295 0.189 0.296 0.521 
IC90 (nM) inhibitory concentration 90% 1118 54.730 0.226 0.338 0.682 
ED50 (nM) effective dose 50% 860 63.303 0.238 0.367 0.677 
EC50 (μg·mL
-1) effective concentration 526 62.576 0.233 0.352 0.685 
IC50 (μg·mL
-1) inhibitory concentration 335 147.952 0.254 0.406 0.687 
EC90 (nM) effective concentration 67 41.936 0.308 0.468 0.884 
IC90 (μg·mL
-1) inhibitory concentration 90% 4 62.001 0.238 0.360 0.699 
       
c2 target protein N(cj) ⟨I
q
1⟩ ⟨I
q
2⟩ ⟨I
q
3⟩ ⟨I
q
4⟩ 
       
CC-CKR-5 C–C chemokine receptor type 5 2304 62.466 0.152 0.243 0.405 
CC-CKR-2 C–C chemokine receptor type 2 2009 64.050 0.170 0.273 0.448 
CC-CKR-3 C–C chemokine receptor type 3 1206 56.723 0.156 0.253 0.410 
CC-CKR-4 C–C chemokine receptor type 4 345 53.788 0.184 0.289 0.505 
CXCR-4 C-X-C chemokine receptor type 4 332 147.452 0.178 0.278 0.497 
HIV-1 RT HIV-1 reverse transcriptase 4029 47.002 0.253 0.384 0.738 
HIV-1 IN HIV-1 integrase 1702 62.249 0.241 0.371 0.674 
HIV-1 PR HIV-1 protease 5946 89.711 0.184 0.288 0.513 
GP160 envelope polyprotein GP160 34 45.879 0.224 0.353 0.611 
       
c3 organism Ni(c2) ⟨I
q
1⟩ ⟨I
q
2⟩ ⟨I
q
3⟩ ⟨I
q
4⟩ 
       
HIV-1 HIV-1 34544 64.299 0.221 0.340 0.630 
mmu Mus musculus 68 64.004 0.157 0.251 0.423 
hsa Homo sapiens 6128 65.954 0.162 0.259 0.430 
HIV-2 HIV-2 1030 81.747 0.198 0.311 0.547 
HIV HIV 1479 52.782 0.203 0.314 0.578 
       
c4 assay N(cj) ⟨I
q
1⟩ ⟨I
q
2⟩ ⟨I
q
3⟩ ⟨I
q
4⟩ 
       
1033994 antiviral activity against HIV1 282 44.250 0.261 0.398 0.752 
708445 effective concentration required for the inhibition of HIV-1 IIIB in MT-4 
cells 
176 102.090 0.158 0.251 0.424 
859312 inhibitory activity was determined against HIV type 1 protease 175 112.916 0.164 0.258 0.450 
659084 inhibitory conc for displacement of [125I]-MIP-1 alpha from human CCR5 
in CHO cell 
141 73.162 0.131 0.210 0.345 
763303 inhibition of HIV-1 protease 118 72.588 0.177 0.269 0.515 
974332 displacement of [125I]MIP1alpha from human CCR5 expressed in CHO 
cells 
109 57.925 0.137 0.219 0.367 
660813 inhibitory activity against recombinant human Chemokine receptor type 3 
(CCR3) expressed in Chinese hamster ovary cells 
108 57.228 0.154 0.248 0.406 
833931 inhibitory activity against wild type HIV-1 LAI cell line 106 46.897 0.306 0.459 0.906 
       
 
 
  
Table 4. Values of Ia0(t) for Some Counties of Different States 
state(s) county name Da
a Ga
b Ia0(t) 
     
AL Autauga County 181 0.405 0.15898072 
AL Baldwin County 188 0.439 0.15695808 
AR Arkansas County 165 0.467 0.15442902 
AR Ashley County 97 0.447 0.15631254 
AZ Apache County 124 0.488 0.15205113 
AZ Cochise County 134 0.435 0.15725717 
CA Alameda County 396 0.456 0.15551203 
CA Amador County 114 0.399 0.15921181 
CO Adams County 179 0.403 0.15906207 
CO Alamosa County 78 0.474 0.15368107 
CT Fairfield County 375 0.537 0.14500381 
CT Hartford County 434 0.458 0.15532361 
FL Alachua County 383 0.516 0.14827275 
FL Baker County 380 0.429 0.15767582 
GA Appling County 105 0.422 0.15811815 
GA Atkinson County 256 0.447 0.15631254 
HI Hawaii County 199 0.458 0.15532361 
HI Honolulu County 201 0.422 0.15811815 
IA Boone County 58 0.407 0.15889508 
Ia Ada County 101 0.435 0.15725717 
ID Bannock County 100 0.429 0.15767582 
IL Adams County 65 0.453 0.15578751 
IN Adams County 21 0.380 0.15968223 
IN Allen County 136 0.428 0.15774207 
KS Allen County 44 0.394 0.15937449 
KS Atchison County 57 0.434 0.15732946 
KY Allen County 71 0.42 0.1582353 
KY Anderson County 76 0.376 0.15972937 
KY Barren County 56 0.455 0.15560481 
LA Acadia Parish 174 0.452 0.15587743 
LA Allen Parish 550 0.434 0.15732946 
LA Ascension Parish 178 0.409 0.15880517 
MA Berkshire County 102 0.462 0.15493541 
MD Allegany County 180 0.446 0.15639665 
MD Calvert County 124 0.369 0.15976727 
ME Hancock County 73 0.437 0.15710961 
MI Allegan County 74 0.402 0.15910113 
MI Barry County 44 0.392 0.15943186 
     
 
a Da is the AIDS prevalence rate in the county a
th in 2010. 
b Ga is the Gini income-inequality measure of the US county in 2010. 
 
  
 
 
 
 
 
Figure 2. ROC curve analysis of LNN (gray color) vs 
MLPs (other colors) classifiers. 
 
 
  
Table 6. Predictions of Some Cases with the LNN Network 
CMPD_ID Laq(cj)obs Laq(cj)pred c-level measure name target organism assay_ID state_county 
          
1172035 1 1 0.37192 IC50 (nM) Nifeviroc CC-CKR-5 hsa 1174016 MO_Laclede 
1172035 1 1 0.41989 IC50 (nM) Nifeviroc CC-CKR-5 hsa 1174015 MO_Macon 
1201187 1 1 0.43568 IC50 (nM) Maraviroc CC-CKR-5 hsa 1034062 MI_Tuscola 
1201187 1 1 0.44035 IC50 (nM) Maraviroc CC-CKR-5 hsa 1019461 MN_Nicollet 
129 1 1 0.36238 IC50 (nM) Zidovudine HIV HIV 640394 IN_Hancock 
175691 1 1 0.55885 IC95 (nM) Rilpivirine HIV HIV 1930128 WA_Mason 
175691 1 1 0.52729 IC95 (nM) Rilpivirine HIV HIV 1930283 WA_Pacific 
308954 1 1 0.32563 IC50 (nM) Etravirine HIV HIV 1006144 GA_Gordon 
308954 1 1 0.31279 IC50 (nM) Etravirine HIV HIV 1006139 GA_Lumpkin 
57 1 1 0.40037 ED50 (nM) Nevirapine HIV-1 HIV-1 709947 TX_Dawson 
57 1 1 0.45551 ED50 (nM) Nevirapine HIV-1 HIV-1 709946 TX_Denton 
114 1 1 0.34536 IC50 (nM) Saquinavir HIV-1 HIV-1 755976 IL_Whiteside 
114 1 1 0.34894 IC50 (nM) Saquinavir HIV-1 HIV-1 868005 CA_Mono 
114 1 1 0.32824 IC50 (nM) Saquinavir HIV-1 HIV-1 866135 CA_Placer 
129 0 0 0.17658 EC50 (nM) Zidovudine HIV-1 HIV-1 884233 NC_Durham 
129 0 0 0.18634 EC50 (nM) Zidovudine HIV-1 HIV-1 688523 NC_Edgecombe 
141 0 0 0.16086 EC50 (nM) Lamivudine HIV-1 HIV-1 1263166 GA_Crisp 
141 0 0 0.15857 EC50 (nM) Lamivudine HIV-1 HIV-1 1263167 GA_DeKalb 
141 0 0 0.13955 EC50 (nM) Lamivudine HIV-1 HIV-1 1263157 GA_Dooly 
484 0 0 0.26125 EC50 (nM) Adefovir HIV-1 HIV-1 1831866 OH_Hocking 
484 0 0 0.17849 EC50 (nM) Adefovir HIV-1 HIV-1 1831858 OH_Jackson 
1163 0 0 0.14076 EC50 (nM) Atazanavir HIV2 HIV-2 991367 MO_Polk 
1163 0 0 0.09766 EC50 (nM) Atazanavir HIV2 HIV-2 991368 MO_Taney 
1163 0 0 0.15377 IC50 (nM) Atazanavir HIV2 HIV-2 1262836 TN_Putnam 
222559 0 0 0.23747 IC50 (nM) Tipranavir HIV2 HIV-2 1264851 TX_Camp 
222559 0 0 0.20195 IC50 (nM) Tipranavir HIV2 HIV-2 1262828 TX_Cass 
625 0 0 0.26799 EC50 (nM) Thiabendazole HIV-1 HIV-1 689145 WI_Jefferson 
          
 
Last, we used this LNN-ALMA model to generate/predict a complex network of the AIDS 
prevalence in the US at county level with respect to the preclinical activity of anti-HIV drugs in 
preclinical assays. The network is bipartite with two classes of nodes (counties vs drugs). In this 
sense, it is a multiscale network similar to the bipartite networks of drugs vs target proteins 
reported by other groups.(76-80) However, the drug nodes of the present network contain 
information about the drug structure as well as all the assay conditions (target protein, organism, 
assay protocol, experimental measure). In addition, the other set of nodes is typical of a social 
network because they contain information about the income inequality in the county. Therefore, 
this complex network is multiscale, linking information about drugs, targets, assays, and society in 
the same line of thinking expressed by Barabasi et al.(81) The links of this complex network are 
the outputs Laq(cj)pred = 1 of our model. That is why we analyzed 43,249 data points to fit the 
model and predict the complex network at the same time. Consequently, we have to include values 
of AIDS prevalence in 2,310 US counties vs ChEMBL results for 21,582 unique drugs, 9 viral or 
human protein targets, 4,856 protocols, and 10 possible experimental measures. In Figure 3, we 
illustrate the subnetwork of AIDS prevalence vs anti-HIV drug preclinical activity for the state of 
Texas. We include some examples of drugs like Efavirenz (ChEMBL223228) and Saquinavir 
(ChEMBL114) with observed and predicted Laq(cj)obs = Laq(cj)pred = 1 effects on AIDS prevalence 
in the counties of Kendall, Jasper, and Victoria, respectively. 
  
 
 
 
Figure 3. Predicted subnetwork of AIDS prevalence vs anti-HIV drug preclinical activity for Texas. 
We used the sensitivity analysis of the ANN module implemented in STATISTICA to detect 
the parameters with the higher contribution to the model. We can conduct the sensitivity analysis 
on the inputs to one ANN by a STATISTICA Neural Networks algorithm. The sensitivity analysis 
ranks the order of input importance by treating each input variable in turn as if it were 
“unavailable”.(82) It is defined a missing value substitution procedure, which allows predictions to 
be made in the absence of values for one or more inputs. To define the sensitivity of a particular 
variable X, the first run uses the network on a set of test cases and accumulates the network error. 
In the second step, the network is employed again using the same cases but replacing the observed 
values of X with the value estimated by the missing value procedure, and again it calculated the 
accumulated network error. By removing the variable X, it is expected for some deterioration in 
error to occur. Therefore, the measure of sensitivity is the ratio of the error with missing value 
substitution to the original error. The more sensitive the network is to a particular input, the greater 
the deterioration is expected, and therefore the greater the ratio. The elimination of a variable with 
ratio ≤1 improves or has no effect on the performance of the ANN. After the sensitivities are 
calculated, they are ranked in order. In Table 7 we can see that the model shows a higher relevance 
to the information about the molecular structure, parameters of type I
q
k. Second, the model ranks 
the information about the organism used to measure the biological activity, parameters of type 
ΔIqk(c3). The third type of relevant input is the experimental measure used to quantify the activity 
of the drug, parameters of type ΔIqk(c1). The fourth ranked inputs in order of importance are 
parameters of type ΔIqk(c2), which quantify the target protein. The fifth type of input quantifies 
information about the assay protocol used to test the drug. The last effect introduced in the model 
was the information about income inequality in the county I
a
0(t). Thus, the sensitivity analysis 
shows that the model is ranked according to the importance of factors in the following order 
(AIDS epidemiology/anti-HIV drug) ≈ structure of drug > organism in preclinical assay > 
experimental measure of activity > drug target > pharmacological assay > county income 
inequality. Table 7 depicts the parameters in decreasing order of their contribution to the model 
(higher contribution => higher ratio => lower rank). The five parameters with higher contribution 
are the following: I
q
2, I
q
4, ΔI
q
2(c3), ΔI
q
2(c1), I
q
3. The parameters of higher contribution for each type 
of information are the following: I
q
2 with rank = 1, ΔI
q
2(c3) rank = 3, ΔI
q
2(c1) with rank = 4, 
ΔIq2(c2) with rank = 13, ΔI
q
2(c4) with rank = 15, and I
a
0(t) with rank = 17 (shown in boldface in 
Table 7). 
We retrained the model using only these parameters, but the new ANN fails to generate good 
predictive models with Sp and Sn < 50%. It means that the model provides a greater importance to 
the chemical structure and pharmacological information (branch A), with respect to county 
information (branch B), but it needs all the parameters. This could be explained taking into 
consideration that branch A includes the higher number of input factors (information considered), 
whereas branch B includes only one input factor, the income-inequality in the county with respect 
to the state. We should also note that the only epidemiological feature used as input to calculate 
the Shannon information indices of the county was the Ga measure of income inequality. The Ga 
measure of income-inequality is widely used as a descriptor to approach the study of the 
epidemiology of different diseases.(83, 84) The values of Ga ≈ 0 are characteristic of societies with 
near-to-ideal equalitarian distribution of income, whereas values of Ga ≈ 1 are typical of inequality 
in income distribution.(85) Gant et al.(86) found a positive value of the Pearson correlation 
coefficient ρ = 0.40 between AIDS diagnosis rates and Ga for 1,560 US counties between 2006 
and 2008. However, they also found a positive correlation (ρ = 0.52) with proportion unmarried – 
ages >15 years. The AIDSVu data presented an average value of Ga = 0.435 and a standard 
deviation of only 0.03. The AIDSVu data set analyzed in this work presents an even weaker 
correlation (ρ = 0.31) between AIDS diagnosis rates in 2010 and Ga for the 2,310 US counties 
studied in this work. It may indicate that possibly we should include other factors in branch B in 
order to collect additional epidemiological information relevant to the present problem. In 
upcoming papers we will continue working on the strategy described here, including other 
information indices of the molecules, other epidemiological factors, different disease transmission 
matrices, and using different types of machine learning algorithms. 
Table 7. Sensitivity Analysis for the LNN Network 
index name of information indices and their MA operatorsa ratio rank 
    
Iq2 Balaban V-index for drugs 532.48 1 
Iq4 Balaban X-index for drugs 336.91 2 
ΔIq2(c3) MA of V-index of drugs assayed in the same organism 263.34 3 
ΔIq2(c1) MA for V-index of drugs with the same experimental measure 254.03 4 
Iq3 Balaban Y-index for drugs 194.36 5 
ΔIq4(c3) MA of X-index of drugs assayed in the same organism 169.38 6 
ΔIq4(c1) MA for X-index of drugs with the same experimental measure 158.25 7 
ΔIq3(c3) MA for Y-index of drugs with the same organism 94.37 8 
ΔIq3(c1) MA for Y-index of drugs with the same experimental measure 94.09 9 
Iq1 Balaban U-index for drugs 10.56 10 
ΔIq1(c1) MA for U-index of drugs with the same experimental measure 5.55 11 
ΔIq1(c3) MA for U-index of drugs with the same organism 5.08 12 
ΔIq2(c2) MA for V-index of drugs with the same protein target 1.09 13 
ΔIq4(c2) MA for X-index of drugs with the same protein target 1.02 14 
ΔIq2(c4) MA for V-index of drugs tested in the same assay 1.01 15 
ΔIq3(c2) MA for Y-index of drugs tested with the same protein target 1.01 16 
Ia0(t) Shannon information index based on the Gini coefficient 1.01 17 
ΔIq4(c4) MA for X-index of drugs tested in the same assay 1.01 18 
ΔIq3(c4) MA for Y-index of drugs tested in the same assay 1.0 19 
    
 
a MA = Moving Average operator of Box-Jenkins. 
 
  
4 Conclusions 
We developed a model called LNN-ALMA to generate complex networks of the AIDS 
prevalence in the US counties with respect to the preclinical activity of anti-HIV drugs. The best 
classifier found was the LNN; the inputs of this classifier are based on Balaban information 
indices. Consequently, this model may be useful to predict the most effective drugs to treat HIV in 
different populations (from the US counties) with a given epidemiological prevalence. In future 
work, we will continue to improve the models, and we will include other information indices, 
social and economic factors, machine-learning techniques, etc. 
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